Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.38 |
| ▸ | UBA3 | Q8TBC4 | 4/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.34 |
| ▸ | AURKA | O14965 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 4/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007085 | 0.83 | NAE1 (0.43) | PI4KAPI4K2BPI4K2API4KBNAE1 | |
| SCHEMBL15007086 | 0.83 | NAE1 (0.43) | PI4KAPI4K2BPI4K2API4KBNAE1 | |
| SCHEMBL18526997 | 0.82 | NAE1 (0.38) | NAE1UBA3RPS6KB1AURKAADORA3 | |
| SCHEMBL782553 | 0.76 | NAE1 (0.67) | NAE1UBA3 | |
| SCHEMBL18526984 | 0.75 | NAE1 (0.47) | PI4KAPI4K2BPI4K2API4KBNAE1 | |
| SCHEMBL2878887 | 0.75 | ERBB2 (0.36) | NAE1UBA3ADORA3ADORA2AADORA1 | |
| SCHEMBL805407 | 0.73 | NAE1 (0.61) | PI4KAPI4K2BPI4K2API4KBNAE1 | |
| SCHEMBL782705 | 0.72 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBNAE1 | |
| SCHEMBL18526990 | 0.71 | EGFR (0.37) | ADORA3ADORA1 | |
| SCHEMBL15007338 | 0.70 | NAE1 (0.46) | NAE1UBA3ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718788-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | PI4KA 1753/4885PI4K2B 2642/4885PI4K2A 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.